In a phase I/II clinical trial, mature DCs enriched with HCC antigens such as α-FP, glypican-3 (GPC-3) were given as a cancer vaccine to patients with advanced HCC and induced an effective T-cells response as evidenced by high levels of IL-12 and IFN-γ production, with radiographic regression and disease stabilization in 13.3% and 60% of patients, respectively [595]. Here, GPC3 is linked to cancer.